PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide with very poor prognosis. Resistance to targeted therapeutic drugs such as sorafenib remains one of the major challenges in clinical treatment. In the present study, PARP1 was found to be highly expressed...

Full description

Bibliographic Details
Main Authors: Xiao-Dong Yang, Fan-En Kong, Ling Qi, Jia-Xin Lin, Qian Yan, Jane Ho Chun Loong, Shao-Yan Xi, Yue Zhao, Yan Zhang, Yun-Fei Yuan, Ning-Fang Ma, Stephanie Ma, Xin-Yuan Guan, Ming Liu
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Molecular Cancer
Subjects:
Pluripotent transcriptome
Embryonic stem cell
Sorafenib resistance
PARP inhibitors
Online Access:https://doi.org/10.1186/s12943-021-01315-9

Internet

https://doi.org/10.1186/s12943-021-01315-9

Similar Items